Cowden syndrome (CS), also known as multiple hamartoma syndrome, is a rare autosomal dominant disorder characterized by the presence of multiple benign tumor-like growths called hamartomas. These growths affect various tissues, including the skin, mucosa, bones, gastrointestinal tract, genitourinary system, eyes, and central nervous system (CNS). Cowden syndrome is also associated with an increased risk of several malignancies, particularly breast, thyroid, and endometrial cancers, which makes early detection critical for effective management. 

The disorder is inherited equally among males and females, although the incidence of malignancies tends to differ by gender. The estimated prevalence of Cowden syndrome is approximately 1 in 250,000 individuals, with the onset of clinical manifestations occurring between birth and approximately 46 years of age.

Genetic Basis and Pathophysiology

The majority of Cowden syndrome cases result from mutations in the PTEN (phosphatase and tensin homolog) gene, a tumor suppressor gene that plays a key role in regulating cell growth, survival, and division. Mutations in PTEN lead to uncontrolled cell proliferation, which causes the formation of hamartomas and predisposes individuals to the development of malignancies, particularly in tissues such as the breast, thyroid, and uterus. Approximately 20% of patients with Cowden syndrome have no identifiable genetic mutation, suggesting that additional genetic or environmental factors may contribute to the disease in some individuals.

Clinical Manifestations

The hallmark of Cowden syndrome is the presence of characteristic benign mucocutaneous lesions, which are present in nearly all affected individuals. These lesions can include:

• Trichilemmomas: Small, flesh-colored papules that most commonly appear around the eyes, nose, and mouth. These benign tumors are considered pathognomonic for Cowden syndrome.
• Oral Mucosal Papillomas: These papules, typically 1-3 mm in size, present as white, smooth-surfaced lesions on the oral mucosa. They often group together, forming a cobblestone-like appearance.
• Acral Keratoses: Wart-like, 1-4 mm papules that develop on the backs of the hands and feet. These are among the most common skin findings in Cowden syndrome.
• Palmoplantar Keratoses: Translucent, punctate, wart-like growths that appear on the palms of the hands and soles of the feet, often manifesting early in the disease.

Additional skin findings can include lipomas (benign fatty tumors), neuromas (nerve tumors), xanthomas (cholesterol deposits), and hemangiomas (benign vascular lesions). The presence of these lesions is typically noted early in life and may serve as key diagnostic clues for healthcare providers.

Diagnosis

The diagnosis of Cowden syndrome is made through a combination of clinical, genetic, and histopathological findings. A thorough medical history, including a family history of malignancies, is essential for identifying individuals at risk for the disorder. Given the increased risk of cancers associated with Cowden syndrome, it is critical to evaluate the patient’s personal and family history of breast, thyroid, and endometrial cancers.

Physical examination is key to identifying the characteristic mucocutaneous lesions. Skin biopsies may be performed on suspicious lesions to confirm the diagnosis. Furthermore, genetic testing for PTEN mutations is the gold standard for confirming Cowden syndrome in individuals with clinical signs. Imaging studies, such as mammography, thyroid ultrasound, and pelvic ultrasound, are recommended for early detection of malignancies. Routine screening for cancers should begin early, as many malignancies associated with Cowden syndrome are treatable if detected at an early stage.

Management and Treatment

The management of Cowden syndrome is multidisciplinary, focusing on controlling the benign lesions, preventing the development of malignancies, and addressing the psychosocial impact of the disorder. Treatment options include both systemic and localized therapies.

• Systemic Therapies:
  • Retinoids: Oral retinoids, particularly systemic isotretinoin, have shown efficacy in reducing the size and number of mucocutaneous lesions associated with Cowden syndrome. Retinoids help regulate cell growth and differentiation, which may also reduce the risk of malignancy.
  • Rapamycin (Sirolimus): Rapamycin, an mTOR inhibitor, has shown promise in clinical trials for the treatment of Cowden syndrome. It has been found to reduce the size of hamartomas and improve the appearance of skin lesions. While still undergoing clinical evaluation, rapamycin offers a potentially new therapeutic option for affected individuals.
• Topical Therapies:
  • Topical treatments, such as retinoids and corticosteroids, have been found to have minimal efficacy in treating the skin lesions of Cowden syndrome, and are not commonly recommended.
• Surgical Interventions:
  • Shave Excision: Lesions such as trichilemmomas and papillomas can be removed via shave excision. However, surgical removal must be approached with caution due to the risk of scarring and recurrence.
  • Laser Therapy and Chemical Peels: For facial lesions, laser resurfacing and chemical peels may be effective in improving cosmetic appearance, although these treatments are primarily cosmetic and do not address the underlying genetic abnormalities.
• Cancer Surveillance and Preventive Care:
  • Close surveillance for cancers of the breast, thyroid, and endometrium is crucial. Patients should undergo annual screening, including mammography, thyroid ultrasound, and pelvic examinations starting at an early age.
  • Patients with Cowden syndrome should be counseled about the importance of regular follow-up visits to monitor for malignancies. Genetic counseling is also recommended to inform patients about the inheritance patterns of the syndrome and the associated cancer risks.
  •  

Conclusion

Cowden syndrome is a rare, genetically inherited disorder that presents with a range of mucocutaneous lesions and increases the risk of various malignancies, particularly in the breast, thyroid, and endometrium. Early recognition through genetic testing and vigilant monitoring for malignancies can significantly improve patient outcomes. Although treatment options for the skin lesions are currently limited, systemic therapies such as retinoids and rapamycin show promise in managing the disease. Ongoing research is necessary to refine treatment strategies and enhance early detection of associated malignancies.

References

1. Michaud, J. D., Cheng, J. K., & Williams, K. M. (2020). Cowden syndrome: Pathophysiology, diagnosis, and treatment. Journal of Clinical Medicine, 9(11), 3729. https://doi.org/10.3390/jcm9113729
2. Ngeow, J., Eng, C. (2021). Cowden syndrome: Epidemiology, diagnosis, and management. Endocrinology and Metabolism Clinics of North America, 50(3), 641-654. https://doi.org/10.1016/j.ecl.2021.04.004
3. Yehia, L., Ngeow, J., & Eng, C. (2017). PTEN and the clinical spectrum of Cowden syndrome: A review of 10 years of clinical and molecular experience. Journal of Clinical Oncology, 35(26), 3028-3037. https://doi.org/10.1200/JCO.2016.70.5451